DYNAMIC CHANGE IN PLASMA EGFR MUTATION DNA IN RESPONSE TO FIRST LINE THERAPY FOR ADVANCED STAGE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Mok, Tony [1 ]
Wu, Yi-Long [2 ]
Lee, Jin Soo [3 ]
Yu, Chong-Jen [4 ]
Sriuanpong, Virotw [5 ,6 ]
Wen, Wei [7 ]
Tsai, Julie [7 ]
Trueman, Matt [8 ]
Klughammer, Barbara [9 ]
Wu, Lin [7 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[3] Natl Canc Ctr, Res Inst & Hosp, Lung Canc Branch, Singapore, Singapore
[4] Natl Taiwan Univ Hosp, Zhongzheng, Taiwan
[5] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[6] Chulalongkorn Univ, Bangkok 10330, Thailand
[7] Roche Mol Syst Inc, Genom & Onocl Dept Res, Pleasanton, CA USA
[8] Roche Prod Ltd, Melbourne, Vic, Australia
[9] Hoffmann la Roche Ltd, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; mutation; plasma DNA; allele-specific PCR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O01.06
引用
收藏
页码：S133 / S134
页数：2
相关论文
共 50 条
  • [21] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schmid, S.
    Schar, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L.
    von Briel, T.
    Waibel, C.
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W. D.
    Siano, M.
    Boos, L.
    Britschgi, C.
    Fruh, M.
    LUNG CANCER, 2024, 187
  • [22] Effects of metformin on a non-small cell lung cancer cell line with an EGFR mutation
    Kitazono, Satoru
    Takiguchi, Yuichi
    Ashinuma, Hironori
    Kitazono, Miyako
    Kitamura, Atsushi
    Tada, Yuji
    Kurosu, Katushi
    Sakaida, Emiko
    Sekine, Ikuo
    Tatsumi, Koichiro
    CANCER RESEARCH, 2012, 72
  • [23] Association of plasma EGFR mutations with response to first-line chemotherapy and prognosis in Chinese patients with advanced non-small cell lung cancer
    Wu, M. N.
    Zhao, J.
    Bai, H.
    Zhuo, M. L.
    Wang, S. H.
    Yang, L.
    An, T. T.
    Wang, X.
    Duan, J. C.
    Wang, Y. Y.
    Wang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gaspar, E.
    Firvida, J.
    Amenedo, M.
    Orts, D.
    Salgado, M.
    LLorca, C.
    Ramos, M.
    Perez, E.
    Cervera, J.
    Abal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] BUDGET IMPACT ANALYSIS OF ERLOTIB AS THE FIRST-LINE THERAPY OF ADVANCED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN VIETNAM
    Tran, T. T.
    Nguyen, T.
    VALUE IN HEALTH, 2016, 19 (03) : A142 - A143
  • [26] EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Cappuzzo, Federico
    Ligorio, Claudio
    Toschi, Luca
    Rossi, Elisa
    Trisolini, Rocco
    Paioli, Daniela
    Magrini, Elisabetta
    Finocchiaro, Giovanna
    Bartolini, Stefania
    Cancellieri, Alessandra
    Hirsch, Fred R.
    Crino, Lucio
    Varella-Garcia, Marileila
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) : 423 - 429
  • [27] Proton therapy for stage I non-small cell lung cancer (NSCLC)
    Nihei, K
    Ogino, T
    Ishikura, S
    Nishimura, H
    Kawashima, M
    Arahira, S
    Onozawa, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S282 - S282
  • [28] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schaer, S.
    Schmid, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L. A.
    Von Briel, T.
    Waibel, C.
    De Nicola, L. Wannesson
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W-D.
    Siano, M.
    Britschgi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
  • [29] Specific organ metastases and survival of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation.
    Shi, Tiantian
    Wang, Long
    Fan, Zhisong
    Feng, Li
    Han, Jing
    Su, Yu
    Zhou, Xinliang
    Zuo, Jing
    Liu, Fengling
    Jiang, Da
    Xu, Xiaoli
    Wang, Yudong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] EGFR mutation and EGFR intron-1 polymorphism predict gefitinib activity in advanced non-small cell lung cancer (NSCLC)
    Franciosi, V.
    Tiseo, M.
    De Palma, G.
    Loprevite, M.
    Chiaramondia, M.
    Rindi, G.
    Naldi, N.
    Bozzetti, C.
    Camisa, R.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 218 - 218
12345